Science news

Oncopeptides today announces the U.S. Food and Drug Administration (FDA) has lifted the clinical hold previously placed on Oncopeptides’ next-gen drug OPD5. 

Oncopeptides AB today announces that a new real-world study on melflufen (melphalan flufenamide, branded in Europe as Pepaxti) plus dexamethasone in patients with relapsed, refractory multiple myeloma (RRMM) has been published in the peer-reviewed journal European Journal of Haematology.

Oncopeptides today announces that an evaluation of the activity of two peptide drug conjugates (PDCs) developed by Oncopeptides in relapsed or refractory Acute Myeloid Leukemia has been accepted as a poster and will be presented at the 66th annual American Society of Hematology (ASH) Meeting and Exposition. The conference takes place in San Diego, California between December 7-10.

Oncopeptides recently announced entry of the first patient in a new study evaluating the real-world effectiveness and safety of Pepaxti in German patients.

Oncopeptides recently announced that the first candidate drug based on the company´s unique platform for Small Polypeptide based innate Killer Engagers (SPiKE) has been selected.

Oncopeptides today announces that new scientific data on melflufen, branded in Europe as Pepaxti, has been accepted at the 10th annual World Congress on Controversies in Multiple Myeloma (COMy), to be held on May 23-26.

Oncopeptides today announces that a new article analyzing scientific data on melflufen, marketed in Europe as Pepaxti, was recently published in the peer-reviewed medical journal Clinical Lymphoma, Myeloma and Leukemia.

Oncopeptides today announces that a new article analyzing health-related quality of life in patients treated with melflufen, marketed in Europe as Pepaxti, has been published in Haematologica.

Oncopeptides recently received a favorable opinion from EMA to revert back to the originally approved indication for Pepaxti. This means that the previously communicated decision to opt out of the process to extend the indication has now been fully realized.

November 17, 2023 - The results further demonstrate efficacy and consistent safety profile in patients with alkylator-refractory disease.

November 13, 2023. Long-term outcomes from its Phase 3 OCEAN study has been accepted as a poster and will be presented at ASH in San Diego, December 9-12.

October 23, 2023. A new article on the Phamacokinetics and metabolism of melflufen, marketed in Europe as Pepaxti, in patients with Relapsed Refractory Multiple Myeloma.

A new article, describing a set of affibody-based NK cell engagers using B cell maturation antigen (BCMA) as a model antigen for targeting of multiple myeloma, has been published online ahead of the November issue of New Biotechnology, the official journal of the European Federation of Biotechnology (EFB). Among the highlights of the article, dual engagers are found effective in activating resting NK cells and inducing a BCMA-dependent killing of MM cells.

Stockholm – September 4, 2023 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that two new articles with scientific data on melflufen, marketed in Europe as Pepaxti, has been published in Haematologica, a publication reporting on important findings...